Literature DB >> 19387346

Advances in treating acute asthma exacerbations in children.

Craig M Schramm1, Christopher L Carroll.   

Abstract

PURPOSE OF REVIEW: Asthma continues to be a major chronic disease in children, and acute asthma exacerbations are common. Although the basic therapy of asthma exacerbations has not changed, recent studies have demonstrated improved outcomes with different modes of delivery of medications, improved patients' self-management of their asthma, and recognition of risk factors for severe exacerbations. RECENT
FINDINGS: Recent studies in children have shown that written action plans based on symptom recognition are more effective than action plans based on peak expiratory flows. Bronchodilator administration by metered-dose inhaler is becoming the preferred therapy for treating mild-to-moderate asthma exacerbations in the emergency department, but nebulizers may still have a role in home and inpatient asthma management. High-dose inhaled corticosteroids may be as effective as oral corticosteroids for acute asthma exacerbations. A novel treatment strategy has titrated combination therapy with budesonide and formoterol for both maintenance and relief of symptoms. Lastly, the contributions of obesity and genetic variation to severe asthma exacerbations are becoming known, and noninvasive positive pressure ventilation has become an option for patients in severe asthma exacerbations.
SUMMARY: Improvements in management strategies can significantly improve outcomes in children with asthma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387346     DOI: 10.1097/MOP.0b013e328329a52f

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  3 in total

1.  Safety and clinical findings of BiPAP utilization in children 20 kg or less for asthma exacerbations.

Authors:  Abby M Williams; Thomas J Abramo; Malee V Shah; Renee A Miller; Cheryl Burney-Jones; Samantha Rooks; Cristina Estrada; Donald H Arnold
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

2.  Transient occult cardiotoxicity in children receiving continuous beta-agonist therapy.

Authors:  Christopher L Carroll; Melinda Coro; Allison Cowl; Kathleen A Sala; Craig M Schramm
Journal:  World J Pediatr       Date:  2014-03-06       Impact factor: 2.764

3.  Budesonide inhalation suspension versus methylprednisolone for treatment of moderate bronchial asthma attacks.

Authors:  Noriyuki Yanagida; Morimitsu Tomikawa; Akinori Shukuya; Masamichi Iguchi; Motohiro Ebisawa
Journal:  World Allergy Organ J       Date:  2015-05-05       Impact factor: 4.084

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.